pLenti6/V5-p53_R280K Citations (2)

Originally described in: Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.
Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW Neoplasia. 2008 May . 10(5):450-61. PubMed

---

Articles Citing pLenti6/V5-p53_R280K

Articles
P53- and mevalonate pathway-driven malignancies require Arf6 for metastasis and drug resistance. Hashimoto A, Oikawa T, Hashimoto S, Sugino H, Yoshikawa A, Otsuka Y, Handa H, Onodera Y, Nam JM, Oneyama C, Okada M, Fukuda M, Sabe H. J Cell Biol. 2016 Apr 11;213(1):81-95. doi: 10.1083/jcb.201510002. Epub 2016 Apr 4. PubMed
ZEB1 induces EPB41L5 in the cancer mesenchymal program that drives ARF6-based invasion, metastasis and drug resistance. Hashimoto A, Hashimoto S, Sugino H, Yoshikawa A, Onodera Y, Handa H, Oikawa T, Sabe H. Oncogenesis. 2016 Sep 12;5(9):e259. doi: 10.1038/oncsis.2016.60. PubMed

If you have published an article using this material, please email us at to have your article added to this page.